Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines

Summary

The purpose of this study is to assess the effect of rosuvastatin (up-titrated to a dose of 40mg/day) compared to placebo on cardiac remodelling, estimated by change in left ventricular ejection fraction on radionuclide ventriculography, at 26 weeks post randomisation from baseline.

Timeline

Start

2003-02

Primary completion

—

Completion

—

Drugs

Indications